Literature DB >> 19545857

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.

Rebecca B Price1, Matthew K Nock, Dennis S Charney, Sanjay J Mathew.   

Abstract

BACKGROUND: Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.
METHODS: Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.
RESULTS: Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).
CONCLUSIONS: These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19545857      PMCID: PMC2935847          DOI: 10.1016/j.biopsych.2009.04.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  17 in total

1.  Implicit attitude measures: consistency, stability, and convergent validity.

Authors:  W A Cunningham; K J Preacher; M R Banaji
Journal:  Psychol Sci       Date:  2001-03

2.  Clinical correlates of inpatient suicide.

Authors:  Katie A Busch; Jan Fawcett; Douglas G Jacobs
Journal:  J Clin Psychiatry       Date:  2003-01       Impact factor: 4.384

3.  Assessment of self-injurious thoughts using a behavioral test.

Authors:  Matthew K Nock; Mahzarin R Banaji
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

4.  Understanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.

Authors:  Anthony G Greenwald; T Andrew Poehlman; Eric Luis Uhlmann; Mahzarin R Banaji
Journal:  J Pers Soc Psychol       Date:  2009-07

5.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Paul J Carlson; Nancy E Brutsche; Rezvan Ameli; David A Luckenbaugh; Dennis S Charney; Husseini K Manji
Journal:  Arch Gen Psychiatry       Date:  2006-08

6.  Antidepressant effects of ketamine in depressed patients.

Authors:  R M Berman; A Cappiello; A Anand; D A Oren; G R Heninger; D S Charney; J H Krystal
Journal:  Biol Psychiatry       Date:  2000-02-15       Impact factor: 13.382

7.  Implicit attitudes towards homosexuality: reliability, validity, and controllability of the IAT.

Authors:  R Banse; J Seise; N Zerbes
Journal:  Z Exp Psychol       Date:  2001

Review 8.  The definition and meaning of treatment-resistant depression.

Authors:  H A Sackeim
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

9.  Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial.

Authors:  Sanjay J Mathew; James W Murrough; Marije aan het Rot; Katherine A Collins; David L Reich; Dennis S Charney
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-17       Impact factor: 5.176

10.  Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression.

Authors:  Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2010-01-15       Impact factor: 13.382

View more
  225 in total

1.  CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.

Authors:  Anita J Bechtholt-Gompf; Karen L Smith; Catherine S John; Hannah H Kang; William A Carlezon; Bruce M Cohen; Dost Ongür
Journal:  Psychopharmacology (Berl)       Date:  2011-01-28       Impact factor: 4.530

Review 2.  Brain-derived neurotrophic factor and neuropsychiatric disorders.

Authors:  Anita E Autry; Lisa M Monteggia
Journal:  Pharmacol Rev       Date:  2012-03-08       Impact factor: 25.468

3.  Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex.

Authors:  Rong-Jian Liu; Francis S Lee; Xiao-Yuan Li; Francis Bambico; Ronald S Duman; George K Aghajanian
Journal:  Biol Psychiatry       Date:  2011-10-29       Impact factor: 13.382

Review 4.  Ketamine for depression: where do we go from here?

Authors:  Marije Aan Het Rot; Carlos A Zarate; Dennis S Charney; Sanjay J Mathew
Journal:  Biol Psychiatry       Date:  2012-06-16       Impact factor: 13.382

Review 5.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

6.  Individual and peer factors associated with ketamine use among adolescents in Taiwan.

Authors:  Kun-Hua Lee; Yi-Chun Yeh; Pin-Chen Yang; Huang-Chi Lin; Peng-Wei Wang; Tai-Ling Liu; Cheng-Fang Yen
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-06-22       Impact factor: 4.785

7.  Cracking the moody brain: lifting the mood with ketamine.

Authors:  James W Murrough; Dennis S Charney
Journal:  Nat Med       Date:  2010-12       Impact factor: 53.440

Review 8.  Translating glutamate: from pathophysiology to treatment.

Authors:  Daniel C Javitt; Darryle Schoepp; Peter W Kalivas; Nora D Volkow; Carlos Zarate; Kalpana Merchant; Mark F Bear; Daniel Umbricht; Mihaly Hajos; William Z Potter; Chi-Ming Lee
Journal:  Sci Transl Med       Date:  2011-09-28       Impact factor: 17.956

Review 9.  Ketamine for treatment-resistant unipolar depression: current evidence.

Authors:  Sanjay J Mathew; Asim Shah; Kyle Lapidus; Crystal Clark; Noor Jarun; Britta Ostermeyer; James W Murrough
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 10.  Pharmacogenomics of suicidal events.

Authors:  David Brent; Nadine Melhem; Gustavo Turecki
Journal:  Pharmacogenomics       Date:  2010-06       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.